New England Journal of Medicine December 28, 2023

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia

Jeffrey L. Carson et al. (MINT Investigators)

Bottom Line

In patients with acute myocardial infarction and anemia, a liberal blood transfusion strategy did not significantly reduce the 30-day risk of recurrent myocardial infarction or death compared to a restrictive strategy, though potential harms of the restrictive approach could not be fully excluded.

Key Findings

1. The primary composite outcome (death or recurrent MI at 30 days) occurred in 16.9% (295 of 1749) of patients in the restrictive-strategy group and 14.5% (255 of 1755) in the liberal-strategy group (Risk Ratio [RR] 1.15; 95% CI, 0.99 to 1.34; P=0.07).

2. All-cause mortality at 30 days was 9.9% in the restrictive group compared to 8.3% in the liberal group (RR 1.19; 95% CI, 0.96 to 1.47).

3. Recurrent myocardial infarction occurred in 8.5% of the restrictive group versus 7.2% of the liberal group (RR 1.19; 95% CI, 0.94 to 1.49).

4. The mean number of red-cell units transfused was significantly lower in the restrictive group (0.7 ± 1.6 units) than in the liberal group (2.5 ± 2.3 units).

5. Transfusion-associated circulatory overload (TACO) occurred less frequently in the restrictive group (0.5%) than in the liberal group (1.3%) (RR 0.35; 95% CI, 0.16 to 0.78).

Study Design

Design

Phase 3 RCT

Open-Label

Sample

3,504

Patients

Duration

30 days

Median

Setting

144 sites, 6 countries

Population Patients with acute myocardial infarction (MI) and a hemoglobin level of less than 10 g/dL

Intervention Restrictive transfusion strategy (hemoglobin threshold for transfusion of 7 or 8 g/dL)

Comparator Liberal transfusion strategy (hemoglobin threshold for transfusion of <10 g/dL)

Outcome Composite of recurrent myocardial infarction or death from any cause at 30 days

Study Limitations

• The open-label design meant that clinicians were aware of the assigned transfusion strategy, which could have influenced adjunctive care, revascularization decisions, and the determination of causes of death.

• The primary outcome narrowly missed statistical significance (P=0.07), preventing definitive statistical conclusions regarding the superiority of a liberal transfusion strategy.

• The trial did not adjust for multiplicity across secondary analyses, meaning secondary endpoint results must be interpreted as hypothesis-generating.

• Cause of death was not centrally adjudicated, and less than half of the mortality events were explicitly classified as cardiac in origin.

Clinical Significance

Although the MINT trial did not cross the threshold for statistical significance, the consistent numerical trend favoring liberal transfusion (lower rates of death and recurrent MI) challenges the universal application of restrictive transfusion thresholds. Unlike general critically ill or surgical populations where restrictive strategies are definitively non-inferior or superior, patients with acute myocardial ischemia may benefit from the increased oxygen-carrying capacity afforded by a liberal strategy (targeting Hb ≥ 10 g/dL). Clinicians must weigh this potential ischemic benefit against the slightly increased risk of transfusion-associated circulatory overload (TACO).

Historical Context

For decades, the optimal hemoglobin threshold for blood transfusion in patients with acute myocardial infarction remained controversial. Landmark trials such as TRICC (1999) in critical care and TRICS III (2017) in cardiac surgery established the safety of restrictive transfusion strategies (typically targeting Hb >7-8 g/dL) to minimize transfusion-related risks. However, patients with acute coronary syndromes were underrepresented or excluded from these studies. Theoretical concerns persisted that anemic MI patients might suffer from reduced myocardial oxygen delivery, thus favoring a liberal strategy. Smaller pilot trials like REALITY and CRIT yielded inconclusive or conflicting results, prompting the design of the MINT trial as the largest and most definitive randomized study to address this critical evidence gap.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Based on the pathophysiology of acute myocardial infarction, why might anemia theoretically exacerbate myocardial injury, and how does this mechanism support the rationale for testing a liberal transfusion strategy?

Key Response

Anemia decreases the oxygen-carrying capacity of the blood, leading to a mismatch in myocardial oxygen supply and demand (classic Type 2 MI physiology). In the setting of an acutely occluded or stenosed coronary artery, reduced collateral oxygen delivery can increase infarct size and precipitate ischemia. This theoretical mechanism underlies the hypothesis that maintaining hemoglobin >10 g/dL (liberal strategy) might salvage ischemic myocardium and improve outcomes.

Resident

You are admitting a patient with an NSTEMI and a hemoglobin of 8.5 g/dL. Based on the MINT trial results, how would you approach the decision to transfuse this patient, and what clinical factors might push you toward a liberal versus restrictive threshold?

Key Response

The MINT trial showed no statistically significant difference in 30-day outcomes, but a trend toward benefit (RR 0.85, 95% CI 0.73-1.00) with the liberal strategy. Therefore, rigid adherence to a restrictive threshold (Hb <8 g/dL) is not strictly mandated in AMI. Residents should individualize the decision by weighing active ischemic symptoms, hemodynamic stability, and the risk of transfusion-associated circulatory overload (TACO) when deciding whether to transfuse a patient with Hb between 8-10 g/dL.

Fellow

The MINT trial included patients with both Type 1 (atherothrombotic) and Type 2 (supply-demand mismatch) myocardial infarctions. How might the underlying pathophysiology of these two MI types influence their respective responses to a liberal transfusion strategy, and what did the trial's subgroup analyses reveal?

Key Response

Type 1 MI involves plaque rupture, where revascularization and antithrombotic therapy are paramount, whereas Type 2 MI in this context is often directly driven by the anemia itself. A liberal strategy might theoretically benefit Type 2 more directly by correcting the primary insult. However, MINT's subgroup analyses did not show a statistically significant interaction by MI type, suggesting that if a benefit exists, it may apply broadly to the ischemic myocardium regardless of the initial trigger, a nuance critical for advanced cardiology triage.

Attending

For years, the 'less is more' paradigm (restrictive transfusion) has dominated hospital medicine based on trials like TRICC and VILLAGE. How do the results of the MINT trial challenge the dogmatic application of a universal restrictive threshold, and how should this influence our teaching on shared decision-making in the CCU?

Key Response

While restrictive strategies are standard for GI bleeds and general critical illness, the MINT trial's confidence interval suggested potential harm with the restrictive strategy in AMI (as the upper bound reached 1.00, leaning toward liberal superiority). Attendings must teach that the heart's oxygen extraction ratio is uniquely high (up to 75% at rest), making it more vulnerable to anemia. The trial permits individualizing care rather than strictly adhering to a generic <7 or <8 g/dL trigger in the CCU.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The MINT trial reported a risk ratio of 0.85 (95% CI, 0.73 to 1.00; P=0.07) for the primary outcome. From a statistical and methodological standpoint, how should the trial's failure to reject the null hypothesis be interpreted in light of the confidence interval, and how might a Bayesian re-analysis alter the interpretation?

Key Response

A frequentist interpretation strictly states no significant difference. However, the 95% CI (0.73 to 1.00) implies that the data are compatible with up to a 27% relative risk reduction with the liberal strategy, with virtually zero probability of harm (RR > 1.0). A Bayesian analysis would likely show a very high posterior probability (often >90%) that a liberal strategy is superior to a restrictive one, highlighting the limitations of rigid p-value thresholds in interpreting large pragmatic trials.

Journal Editor

Given that transfusion trials like MINT cannot be blinded to the clinical team, what are the primary threats to internal validity regarding crossover or protocol non-adherence, and how does the actual separation of hemoglobin levels between the two arms impact the trial's power?

Key Response

Open-label designs risk protocol violations (e.g., clinicians transfusing the restrictive group due to perceived clinical need, or withholding blood in the liberal group due to volume overload fears). If the actual mean hemoglobin difference achieved between the groups is small, the trial's statistical power is significantly diluted, potentially driving results toward the null. A rigorous editorial review would heavily scrutinize the per-protocol analysis and the delta in median hemoglobin levels achieved.

Guideline Committee

Prior guidelines (e.g., AABB) recommended restrictive thresholds (7-8 g/dL) for hemodynamically stable patients but noted uncertainty in acute coronary syndromes. Based on the MINT trial, how should guidelines update recommendations regarding transfusion thresholds in AMI?

Key Response

Given MINT's finding of no definitive significant benefit but a strong trend suggesting potential harm with the restrictive approach, guidelines cannot give a Class I recommendation for a liberal strategy. Instead, they should issue a Class IIb recommendation stating a liberal strategy (target Hb 10 g/dL) 'may be considered' in AMI, especially for those with ongoing ischemia, clearly distinguishing AMI from general critical care where strict restrictive strategies (Hb <7 g/dL) remain a Class I recommendation.

Clinical Landscape

Noteworthy Related Trials

1999

TRICC Trial

n = 838 · NEJM

Tested

Restrictive transfusion strategy (Hb < 7.0 g/dL)

Population

Critically ill ICU patients

Comparator

Liberal transfusion strategy (Hb < 10.0 g/dL)

Endpoint

30-day mortality

Key result: A restrictive transfusion strategy was at least as effective as a liberal strategy, with lower mortality in less severely ill and younger patients.

2011

FOCUS Trial

n = 2,016 · NEJM

Tested

Restrictive transfusion strategy (Hb < 8.0 g/dL)

Population

Patients older than 50 years with high cardiovascular risk undergoing hip surgery

Comparator

Liberal transfusion strategy (Hb < 10.0 g/dL)

Endpoint

Death or inability to walk independently at 60 days

Key result: A restrictive transfusion strategy did not increase rates of death or functional decline compared to a liberal strategy.

2021

REALITY Trial

n = 668 · JAMA

Tested

Restrictive transfusion strategy (Hb < 8.0 g/dL)

Population

Patients with acute myocardial infarction and anemia

Comparator

Liberal transfusion strategy (Hb < 10.0 g/dL)

Endpoint

30-day major adverse cardiovascular events (MACE)

Key result: A restrictive transfusion strategy was non-inferior to a liberal strategy in preventing MACE at 30 days among patients with acute MI and anemia.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis